×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAZZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/27
07:36 pm
jazz
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative [Yahoo! Finance]
Low
Report
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative [Yahoo! Finance]
4/27
07:14 pm
jazz
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks [Yahoo! Finance]
Low
Report
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks [Yahoo! Finance]
4/27
10:30 am
jazz
Jazz Pharmaceuticals Scores FDA Priority Review for Ziihera Combinations in First-Line HER2+ Gastroesophageal Cancer [TheStreet.com]
Low
Report
Jazz Pharmaceuticals Scores FDA Priority Review for Ziihera Combinations in First-Line HER2+ Gastroesophageal Cancer [TheStreet.com]
4/27
08:03 am
jazz
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA [Yahoo! Finance]
4/27
07:45 am
jazz
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Low
Report
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
4/24
08:07 pm
jazz
Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225 [Yahoo! Finance]
Low
Report
Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225 [Yahoo! Finance]
4/23
04:18 am
jazz
Tuberous Sclerosis Complex Market Research and Global Long-term Forecast Report 2026-2035 Featuring Prominent Players - Novartis, Jazz Pharmaceuticals, Nobelpharma America [Yahoo! Finance]
Medium
Report
Tuberous Sclerosis Complex Market Research and Global Long-term Forecast Report 2026-2035 Featuring Prominent Players - Novartis, Jazz Pharmaceuticals, Nobelpharma America [Yahoo! Finance]
4/22
03:53 pm
jazz
HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties [Yahoo! Finance]
Low
Report
HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/24/2026
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
13.2%
jazz pharmaceuticals plc - ordinary shares
11/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-2.3%
jazz pharmaceuticals plc - ordinary shares
8/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-6.4%
jazz pharmaceuticals plc - ordinary shares
5/6/2025
04:08 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-3.4%
jazz pharmaceuticals plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/24
04:09 pm
jazz
Form 10-K/A Jazz Pharmaceuticals For: Dec 31
Low
Report
Form 10-K/A Jazz Pharmaceuticals For: Dec 31
4/3
05:10 pm
jazz
Form 4 Jazz Pharmaceuticals For: Apr 01 Filed by: COZADD BRUCE C
Low
Report
Form 4 Jazz Pharmaceuticals For: Apr 01 Filed by: COZADD BRUCE C
4/1
04:04 pm
jazz
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
Low
Report
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
3/27
10:21 am
jazz
Form SCHEDULE 13G/A Jazz Pharmaceuticals Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Jazz Pharmaceuticals Filed by: VANGUARD GROUP INC
3/9
05:31 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: COZADD BRUCE C
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: COZADD BRUCE C
3/9
05:27 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Johnson Philip L
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Johnson Philip L
3/9
05:25 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Henderson Mary Elizabeth
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Henderson Mary Elizabeth
3/9
05:23 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Pearce Samantha
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Pearce Samantha
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat
9.3%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
TOP News Decliners
3/13
Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK
-11.3%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: